Previous pre-clinical studies targeting PD-1 in a TIL-based ACT context have reported average expression reductions of 76% using zinc finger nucleases (ZFNs) in melanoma23 and up to a 72% reduction using transcription activator-like effector endonucleases (TALENs) in breast cancer.24 The gene discussed is PDCD1; the disease is breast cancer.